Abstract
Background Long COVID (LC) is a novel condition that is characterized by persistent symptoms that last from months to years following a SARS-CoV-2 infection. While LC symptoms vary widely, neuropathy is one of the most prevalent symptoms and drastically affects patients’ quality of life. However, the underlying pathophysiology of LC neuropathy remains poorly understood. Here, we investigated the prevalence and potential mechanisms of LC neuropathy in the largest LC neuropathy cohort to date.
Methods We conducted an observational study of 977 adults with LC at Dell Medical School. Participants underwent clinical assessments, skin punch biopsy, and comprehensive metabolic, endocrine and immunological profiling. A subset of patients received treatment with intravenous immunoglobulin (IVIG).
Findings Neuropathic symptoms were reported by 55% (534/977) participants, with skin biopsy confirming small fiber neuropathy in 56.5% (48/85) cases, affecting both epidermal and autonomic nerve fibers. Common risk factors for neuropathy, including metabolic and endocrine disorders, did not fully explain neuropathic symptoms. While general immunological markers (lymphocyte, T cell, and B cell count and C reactive protein were unremarkable, unexpectedly, we detected anti-ganglioside antibodies (AGAs) in 25% of patients with LC neuropathy, a comparable rate to other AGA-associated neuropathies. Longitudinal testing revealed persistent AGA positivity, and multiple elevated AGAs in a subset of patients. In a pilot treatment cohort of eight patients, IVIG treatment resulted in improvement of patient reported neuropathic symptoms.
Interpretation Our findings reveal a high prevalence of small fiber neuropathy in LC, with evidence suggesting an autoimmune mechanism involving AGAs in one in four LC neuropathy patients. The therapeutic response to IVIG further supports an autoimmune pathophysiology, suggesting potential benefits of immunomodulation in LC neuropathy patients.
Competing Interest Statement
EM is a principal investigator on a subcutaneous immunoglobulin clinical trial (CSL-Behring) for post-COVID Postural Orthostatic Tachycardia Syndrome. WMB and JB are co-investigators on the same study. The other authors declare no competing interests.
Funding Statement
This work was supported by The University of Texas at Austin Graduate School Continuing Fellowship (C.M.), philanthropic funds from Mr. Tom Bonney (E.M), NIAAA K08AA027837-05 (E.M.), The University of Texas at Austin Research and Creative Grant Award (E.M.), and institutional Dell Medical School Startup funding (E.M.). Funding sources did not have a direct role in design, analysis, or approval of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For retrospective electronic health record analysis, The University of Texas at Austin Institutional Review Board reviewed the study protocol and determined it met the criteria for exemption from IRB review under 45 CFR 46.104 (4) secondary research on data or specimens. For research blood samples, all participants gave written informed consent in adherence to all local and national regulations and the study was approved by the UT Austin Institutional Review Board (IRB ID: STUDY00002467).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 2G was updated to clarify the rate of indeterminate results from skin punch biopsy; minor changes to the text to clarify existing statements; grammatical errors were corrected.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
